Ampion effective in study, Ampio shares soar

|About: Ampio Pharmaceuticals, Inc. (AMPE)|By:, SA News Editor

Ampio Pharmaceuticals (AMPE) soars 34% premarket after saying the endogenous immunomodulatory molecule Ampion met its primary endpoint in a study evaluating the treatment's ability to reduce pain in patients with osteoarthritis of the knee.

Orthopedic surgeon Dr. Brian McGrath, the study's principal investigator, calls the results "fantastic" and notes that it "may soon be possible to offer OAK patients an effective [injectable] therapy." (PR)